Oaktree Acquisition Corp III Life Sciences(OACC.US)

Company Encyclopedia

Oaktree Acquisition Corp III Life Sciences

OACC.US

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe.

1.236 T

OACC.USMarket value -Rank by Market Cap -/-

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Brookfield Corporation	19.52%	No Change	27/03/2025
AQR Capital Management, LLC	5.75%	-38.00 K	30/09/2025
Barclays PLC	5.28%	No Change	31/03/2025
The Toronto-Dominion Bank	3.8%	179.02 K	30/09/2025
D. E. Shaw & Co., L.P.	3.51%	No Change	30/09/2025
Boussard & Gavaudan Asset Management LP	3.05%	No Change	30/09/2025
Empyrean Capital Partners, LP	3.05%	No Change	30/09/2025
Driehaus Capital Management LLC	2.9%	-44.28 K	30/09/2025
HighTower Advisors, LLC	2.68%	-29.07 K	30/09/2025
Decagon Asset Management LLP	2.62%	26.31 K	30/09/2025

News

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Shares Up 0.3% - Still a Buy?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) shares rose 0.3% to $10.60, despite a "sell" rating from Weiss Ratings. Trading volume was significantly lower than average. Institutional investors have adjusted their positions, with notable purchases by Driehaus Capital Management and Lighthouse Investment Partners. Analysts suggest other stocks may be better investments.

Market Beat·12/11/2025 15:26

OACC

+0.19%

Market Beat·12/11/2025 15:26

OACC

+0.19%

Oaktree Acquisition Corp III Life Sciences | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings·11/14/2025 06:05

OACC

+0.19%

LB filings·11/14/2025 06:05

OACC

+0.19%

Oaktree Acquisition Corp. III Life Sciences Announces CFO Transition

Oaktree Acquisition Corp. III Life Sciences announced the resignation of CFO Thomas Sweeney, effective October 29, 2025, to pursue other professional opportunities. George A. Martinez has been appointed as the new CFO, also effective the same day. Martinez previously served as Senior VP at Oaktree and was a former Audit Senior Manager at Ernst & Young.

TradingView·10/30/2025 05:05

OACC

+0.19%

TradingView·10/30/2025 05:05

OACC

+0.19%

Oaktree Acquisition Corp. III Life Sciences Appoints New Independent Director

Oaktree Acquisition Corp. III Life Sciences has appointed Dr. David A. Berry as an independent director, effective October 17, 2025. Dr. Berry will also serve on the audit, nominating, and compensation committees. He is a co-founder of Averin Capital and a former CEO of Valo Health, bringing extensive board experience to the role.

TradingView·10/18/2025 05:25

OACC

+0.19%

TradingView·10/18/2025 05:25

OACC

+0.19%

Oaktree Acquisition Corp III Life Sciences | 10-Q: FY2025 Q2 EPS: USD 0.08

LB filings·08/12/2025 21:16

OACC

+0.19%

LB filings·08/12/2025 21:16

OACC

+0.19%